Serum levels of interleukin-12 in patients with gastrointestinal cancer

被引:0
作者
Nakayama, Y [1 ]
Shibao, K [1 ]
Sako, T [1 ]
Ohta, R [1 ]
Onitsuka, K [1 ]
Hirata, K [1 ]
Nagata, N [1 ]
Itoh, H [1 ]
机构
[1] Univ Occupat & Environm Hlth, Dept Surg 1, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan
关键词
interleukin-12; gastric cancer; colorectal cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interleukin 12(IL-12) is a heterodimeric cytokine that has potent anti-tumor and anti-metastatic activities. Although clinical trials of recombinant human IL-12 have begun in patients with several advanced malignancies, very few studies have investigated the preoperative serum levels of IL-12 in patients with gastric or. colorectal cancel: The purpose of the present study was to investigate the relationships between the preoperative serum levels of IL-12 and clinicopathological factors in patients with gastric ol colorectal cancer Blood was obtained before surgery from 14 patients with gastric cancer a,ld 15 patients with colorectal cancer Serum levels of IL-12 was assesed using the quantitative sandwich enzyme immunoassay technique. Although not statistically significantly; low serum levels of IL-12 tended to be associated with gastric cancer patients who were node-positive, CEA positive, han tumors that penetrated the serosa, had turners greater than 5cm in diameter; were more than 60 years-old or were more advanced than stage IIIA(TNM) or stage IIIa(Japanese Research Society for Gastric Cancer). Patients with colorectal cancer who were node-positive, had tumors that penetrated the serosa, were mole than 60 years-old, or were more advanced than stage III(TNM), stage IIIa (Japanese Society for Cancel of the Colon and Rectum) and Dukes' C also tended to have low serum IL-12 levels. these results suggest that low serum levels of IL-12 may be observed in more advanced gastric and cob-ectal cancer patients. Thus, patients with low serum levels of IL-12 in gastric or colorectal cancer ma)! require additional immunochemotherapy after surgery.
引用
收藏
页码:635 / 640
页数:6
相关论文
共 45 条
[1]  
ANDREWS JVR, 1993, J IMMUNOTHER, V14, P1
[2]   HUMAN INTERFERON-INDUCIBLE PROTEIN-10 IS A POTENT INHIBITOR OF ANGIOGENESIS IN-VIVO [J].
ANGIOLILLO, AL ;
SGADARI, C ;
TAUB, DD ;
LIAO, F ;
FARBER, JM ;
MAHESHWARI, S ;
KLEINMAN, HK ;
REAMAN, GH ;
TOSATO, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :155-162
[3]  
Atkins MB, 1997, CLIN CANCER RES, V3, P409
[4]   INTERLEUKIN-12 - A NEW CLINICAL PLAYER IN CYTOKINE THERAPY [J].
BANKS, RE ;
PATEL, PM ;
SELBY, PJ .
BRITISH JOURNAL OF CANCER, 1995, 71 (04) :655-659
[5]   ANTITUMOR AND ANTIMETASTATIC ACTIVITY OF INTERLEUKIN-12 AGAINST MURINE TUMORS [J].
BRUNDA, MJ ;
LUISTRO, L ;
WARRIER, RR ;
WRIGHT, RB ;
HUBBARD, BR ;
MURPHY, M ;
WOLF, SF ;
GATELY, MK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (04) :1223-1230
[6]  
BRUNER CA, 1995, REV MEX PSICOL, V12, P7
[7]  
Colombo MP, 1996, CANCER RES, V56, P2531
[8]   PRODUCTION OF NATURAL-KILLER-CELL STIMULATORY FACTOR (INTERLEUKIN-12) BY PERIPHERAL-BLOOD MONONUCLEAR-CELLS [J].
DANDREA, A ;
RENGARAJU, M ;
VALIANTE, NM ;
CHEHIMI, J ;
KUBIN, M ;
ASTE, M ;
CHAN, SH ;
KOBAYASHI, M ;
YOUNG, D ;
NICKBARG, E ;
CHIZZONITE, R ;
WOLF, SF ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (05) :1387-1398
[9]  
DELPRETE G, 1994, LAB INVEST, V70, P299
[10]  
GATELY MK, 1986, J IMMUNOL, V136, P1274